Therapeutic doses of plasma rich in growth factors cannot provoke cancer by means of the IGF-1 pathway or inflammation in dogs
Vilar, J.M., Damiá, E., Rubio, M., Santana, A., Sopena, J., Ceron, J.,
Tvarijonaviciute, A., Cugat, R., Carrillo, J.M.
Abstract
A potential relationship between an increased risk of cancer and increased levels of serum insulin-like growth factor-1 (IGF-1), and presence of cancer and high levels of C-reactive protein (CRP) has been previously reported. This study evaluated the influence of a single intramuscular injection of plasma rich in growth factors (PRGF) on serum concentrations of IGF-1 and CRP in dogs. Two groups of eight healthy beagles were injected with two different doses of PRGF in lumbar muscles. For each treatment, IGF-1 and CRP were analysed from blood samples obtained at baseline and the following three days post injection. No differences were found when IGF-1 and CRP were compared among times in the two protocols. Local application of PRGF at clinical doses did not cause significant changes in systemic concentrations of IGF-1 or detectable inflammation. © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
Article
